Colorectal cancer (CRC) remains one of the most common cancers in the world, and approximately 5–10 % of cases can be attributed to hereditary syndromes, including familial adenomatous polyposis, Lynch syndrome, MYH-associated polyposis, the hamartomatous syndromes, and their variants. Extensive research has identified the genes associated with many of these syndromes. Screening and management of patients with these conditions differs from that of the general population, and genetic testing and counselling has become crucial in this process. In this review, we discuss the different hereditary polyposis syndromes and their genetics, and emphasise approaches to the screening and surveillance of patients in the hope of preventing the morbidity and mortality currently associated with CRC.
Share this Article
Related Content In Gastrointestinal Oncology
Treatment Options in BRAF-mutant Metastatic Colorectal Cancer
touchREVIEWS in Oncology & Haematology. 2022;18(2):103-6 DOI: https://doi.org/10.17925/OHR.2022.18.2.103
Until recently, treatment options for metastatic colorectal cancer (CRC) have been limited to a cytotoxic chemotherapy with or without an anti-epithelial growth-factor receptor (EGFR) monoclonal antibody, namely cetuximab and panitumumab, or an anti-angiogenic agent such as bevacizumab, aflibercept or ramucirumab. For subsequent lines of treatment, the tyrosine kinase inhibitor regorafenib is an important part of […]
Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers
touchREVIEWS in Oncology & Haematology. 2022;18(1):16–25 DOI: https://doi.org/10.17925/OHR.2022.18.1.16
Gastro-oesophageal cancers (GEC), which include both gastric (GC) and oesophageal cancers (EC), are among the most common cancers globally.1 In the USA, the American Cancer Society estimated 20,640 new diagnoses of EC and 26,380 new diagnoses of GC, each contributing to 16,410 and 11,090 deaths, respectively, in 2022 alone.2,3 GEC is divided based on the histology of squamous […]
Cholangiocarcinoma: The Present and Future of Targeted Therapies
touchREVIEWS in Oncology & Haematology. 2022;18(1):9–15 DOI: https://doi.org/10.17925/OHR.2022.18.1.9
Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. While they account for around 3% of all gastrointestinal malignancies, they are the second most common primary liver cancer.1 CCAs tend to metastasize and have early lymph node involvement. As a result, only a small proportion of patients are considered for surgical management, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!